GE Healthcare is leading the CZT revolution. It started with the investment in its manufacturing and the introduction of dedicated cardiac and breast imaging systems powered by cadmium zinc telluride (CZT) technology. Now it is accessible in the world’s first commercially available general purpose SPECT/CT system, Discovery NM/CT 670 CZT. The Discovery NM/CT 670 CZT is engineered to reduce dose or time by 75 percent1 and improve lesion detection2, image quality and patient comfort. Combined with advanced quantitative applications provided through Xeleris 4.0, it can help clinicians continue their efforts to diagnose and stage diseases earlier.
1 Together with Clarity 2D/Evolution and compared to D670Pro/ES/DR without Clarity 2D/Evolution
2 Improved detectability as demonstrated in phantom testing